Korinth M C
Department of Neurosurgery, University Hospital RWTH, Aachen, Germany.
Acta Neurochir (Wien). 2006 Nov;148(11):1189-96; discussion 1196. doi: 10.1007/s00701-006-0868-4. Epub 2006 Sep 21.
Increasing numbers of patients presenting for intracranial surgery are receiving concurrent medication with low-dose aspirin, leading to dysfunctional circulating platelets, which might increase the peri-operative risk of bleeding.
To survey the opinions and working practices of neurosurgical facilities in Germany regarding patients who present with low-dose aspirin medication before elective intracranial surgery. Methods. Questionnaires were sent to 210 neurosurgical facilities asking five main questions: (1) the adherence of any policy of stopping aspirin pre-operatively, (2) the personal risk assessment for patients with brain surgery under low-dose aspirin medication, (3) the preferred method of treatment for excessive bleeding in this context, (4) personal knowledge of haemorrhagic complications in this group of patients, and (5) the characteristics of the neurosurgical units concerned.
There were 138 (65.7%) valid responses. Of the respondents, 111 (80.4%) had a departmental policy for the discontinuation of pre-operative aspirin treatment. The mean time for discontinuation of aspirin pre-operatively was 7.3 days (range: 0-21 days). 107 respondents (77.5%) considered that patients taking low-dose aspirin were at increased risk for excessive peri-operative haemorrhage, and 80 (58%) reported having personal experience of such problems. Ninety-seven respondents (70.3%) would use special medical therapy, preferably desmopressin, if haemorrhagic complications developed intra-operatively. The mean amount of intracranial operations per year in each neurosurgical facility was 494 (range: 50-1700).
The majority of neurosurgical facilities in Germany have distinct departmental policies concerning the discontinuation of low-dose aspirin pre-operatively, with an average of 7.3 days. Three-quarter of the respondents felt that aspirin was a risk factor for haemorrhagic complications associated with intracranial procedures, and more than half of the interviewees reported having personal experience of such problems. Various medicamentous methods of counteracting aspirin-induced platelet dysfunction and excessive bleeding in this context are discussed and evaluated.
越来越多接受颅内手术的患者同时服用小剂量阿司匹林,导致循环血小板功能异常,这可能会增加围手术期出血风险。
调查德国神经外科机构对于择期颅内手术前服用小剂量阿司匹林患者的看法和工作实践。方法。向210个神经外科机构发放问卷,询问五个主要问题:(1)术前停用阿司匹林的政策遵守情况,(2)服用小剂量阿司匹林的患者进行脑部手术的个人风险评估,(3)这种情况下处理出血过多的首选治疗方法,(4)对该组患者出血并发症的个人了解情况,以及(5)相关神经外科单位的特点。
有138份(65.7%)有效回复。在受访者中,111人(80.4%)所在科室有术前停用阿司匹林治疗的政策。术前停用阿司匹林的平均时间为7.3天(范围:0 - 21天)。107名受访者(77.5%)认为服用小剂量阿司匹林的患者围手术期出血过多的风险增加,80人(58%)报告有此类问题的个人经验。97名受访者(70.3%)表示,如果术中出现出血并发症,会使用特殊药物治疗,首选去氨加压素。每个神经外科机构每年的颅内手术平均数量为494例(范围:50 - 1700例)。
德国大多数神经外科机构对于术前停用小剂量阿司匹林有明确的科室政策,平均为7.3天。四分之三的受访者认为阿司匹林是颅内手术相关出血并发症的危险因素,超过一半的受访者报告有此类问题的个人经验。本文讨论并评估了在这种情况下对抗阿司匹林诱导的血小板功能异常和出血过多的各种药物方法。